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Background: Compound Valeriana jatamansi Jones is a formula for treating anxiety-related diseases in the clinic,
which is composed of Valeriana jatamansi Rhizoma et Radix, Ziziphi Spinosae Semen, Albiziae Cortex and Junci
Medulla. The purpose of this study was to explore the anxiolytic properties of this compound in mice.
Methods: Male ICR mice were treated with compound Valerianae Jatamansi Jones (1.2 g/kg, 2.4 g/kg, 4.8 g/kg),
saline, diazepam (2 mg/kg) orally for 10 days and then exposed to elevated maze-plus (EPM) and light–dark box
(LDB). The effects of the compound on spontaneous activity were evaluated by locomotor activity test. We further
investigated the mechanism of action underlying the anxiolytic-like effect of compound by pre-treating animals
with antagonists of benzodiazepine (flumazenil, 3mg/kg) prior to evaluation using EPM and LDB.
Results: Compound Valerianae Jatamansi Jones (2.4, 4.8 g/kg, p.o.) significantly increased entries (P<0.05) into and
time spent (P<0.05) on the open arms of the EPM, and number of transitions (P<0.05) and time spent (P<0.05) in
the light compartment of the LDB. However, the anxiolytic-like effects of compound were significantly reduced by
pre-treatment with flumazenil (P>0.05). In addition, compound Valerianae Jatamansi Jones treatment didn’t affect
the spontaneous activity in mice (P> 0.05).
Conclusions: The present study supports the hypothesis that compound Valeriana jatamansi Jones exert anxiolytic
action but no sedative effects in mice and that this effect might be mediated by benzodiazepine receptors.
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receptorsBackground
Anxiety disorders are the most common and prevalent
behavioral disorders that can result in significant im-
pairment of function and quality of life, and they affect
17.2% of the population in the United States [1].
Currently, pharmacotherapy is the most widespread and
efficacious treatment for anxiety disorders [2]. Benzodia-
zepines are the most common class of compounds used
for anxiety [3]. However, the short-term use of benzodia-
zepines interferes with the formation of new memories.
Moreover, it can induce complete anterograde amnesia
[4]. Studies reported that between 20–100% of patients
experienced withdrawal symptoms, sedation, and de-
pendence when they took benzodiazepines at therapeutic* Correspondence: shijl@vip.sina.com; guojianyou@126.com
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reproduction in any medium, provided the ordoses for prolonged periods [5]. Therefore, the develop-
ment of other anxiolytic drugs without the adverse
effects of benzodiazepines would significantly improve
the treatment of anxiety disorders.
Traditional Chinese Medicine has been commonly
recognized as a safe and effective means of treating
anxiety disorders [6-8]. The compound Valeriana jata-
mansi Jones is used to treat anxiety-related diseases [9],
and is composed of Valeriana jatamansi Rhizoma et
Radix (12g), Ziziphi Spinosae Semen (9g), Albiziae Cor-
tex (9g) and Junci Medulla (1g). The anxiolytic effects
of this formulation have been previously established in the
rat [10]. However, considering its low affinity for benzodi-
azepine binding site in binding assays, it is unclear
whether this anxiolytic activity was mediated by this site
modulation at γ-aminobutyric acid (GABA)-A receptors.
In addition, chromatographic profiling of this formulation
for purity was not carried out in previous study [10].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lytic effects of compound Valeriana jatamansi Jones in
mice using the elevated plus maze (EPM), light/dark box
(LDB) test, and spontaneous activity. The formulation
was first evaluated for purity by high-performance liquid
chromatography (HPLC). We also examined whether its
anxiolytic effects are mediated by GABA(A) receptors




Valeriana jatamansi Rhizoma et Radix was purchased
from a commercial source in Yunnan province, China.
Ziziphi Spinosae Semen, Albiziae Cortex, and Junci Me-
dulla were purchased from a commercial source in
Hebei province, China. The identity of the herbal medi-
cine was confirmed by Professor Shi, a researcher in the
Department of Pharmacognosy, Beijing University of
Chinese Medicine. Voucher specimens were deposited at
the Herbarium of School of Chinese Materia Medica,
Beijing University of Chinese Medicine.
Preparation of the extracts
Previous chemical and pharmacological studies in our
laboratory demonstrated that the compound Valeriana
jatamansi Jones has optimum efficacy when the four
herbal components were extracted by different solvents.
Jatamana Valeriana Rhizome was homogenized to
coarse powder, refluxed three times each for 2h in
aqueous ethanol (35%, 2L, v/v), and the combined alco-
holic extract was filtered and evaporated (yield 20.7%
(w/w)). Albiziae Cortex and Ziziphi Spinosae Semen
were also homogenized to coarse powder, infused in 2L
of cold distilled water, and extracted for 3h twice by
heating. Then, the extracts were concentrated to dry-
ness. The yield of the extracts of Albiziae Cortex and
Ziziphi Spinosae Semen were 15.2% and 25.8% (w/w),
respectively. Junci Medulla was refluxed for 1.5h in
aqueous ethanol (95%, 1.5L, v/v) three times, and the
combined alcoholic extract was filtered and concen-
trated (yield 4.5% (w/w)). Based on the original formu-
lation and the herb extraction yield, the four extracts
(Valeriana jatamansi Rhizoma et Radix, Ziziphi Spino-
sae Semen, Albiziae Cortex and Junci Medulla) were
mixed with a ratio of 5:3:5:1 to get the compound
Valeriana jatamansi Jones.
Chromatographic conditions of HPLC
9.80 mg hesperidin reference substance (Lot 110721–
200512, the National Institute for the Control of
Pharmaceutical and Biological Products, China) was
transferred into a 25 mL measuring flask and mixed with
methanol. Then, the mixture was shaken and filteredthrough 0.45μm filters. 5g of mixed dry extracts were
used to prepare the sample solution and refluxed in an
appropriate amount of methanol to a colorless extract
and filtered. Then, it was transferred to a 100mL meas-
uring flask and brought up to level with methanol and
filtered through 0.45μm filters. 5μL solutions were
injected. The samples were chromatographed using an
AgilentW C18 chromatographic column (5 μm, 250 ×
4.6mm), a mobile phase consisting: acetonitrile - 0.3%
phosphoric acid (20∶80, v/v), a flow rate of 1mL/min, a
column temperature of 35°C, and UV detection at
280nm.Drugs
The following drugs were used in the study: diazepam
hydrochloride (2.5mg/tab.), three different concentra-
tions (1.2, 2.4, 4.8 g/kg) of the compound Valeriana
jatamansi Jones and flumazenil (Sigma, St Louis, MO,
USA). For oral (p.o.) administration for 10 days, com-
pound Valeriana jatamansi Jones and diazepam were dis-
solved in saline. Each drug was administered in a
volume of 0.4mL/25g body weight. Control animals
received vehicle (saline, 0.4mL/25g) only. For evaluating
the anxiolytic effects of the compound Valeriana jata-
mansi Jones, the mice were administered the compound
Valeriana jatamansi Jones (1.2, 2.4, 4.8 g/kg) or diaze-
pam 60 and 30min before the test, respectively. For
exploring the anxiolytic mechanisms of the compound
Valeriana jatamansi, the mice were also administered
the compound Valeriana jatamansi Jones (1.2, 2.4,
4.8 g/kg) or diazepam for 10 days described above. On
the last day, flumazenil (GABA(A) antagonist) was co-
administered (i.p., 3mg/kg) 30 min before the test. All of
the animal tests were performed on the 10th day of
treatment.Animals
Male Imprinting Control Region (ICR) mice weighing
18–22g were purchased from the China Academy of
Military Medical Sciences and kept in cages of 5 mice at
22 ± 1°C on a 12-h light/dark cycle (with lights on from
08:00–20:00). Water and food were available ad libitum.
Groups of 12–20 mice were randomly assigned to differ-
ent treatment groups and tested in a counterbalanced
order. All experiments were carried out in a quiet room
under a dim red light between 8:00 and 14:00. The ex-
perimental procedures were approved by the Institu-
tional Animal Care and Use committee of the Institute
of Psychology of the Chinese Academy of Sciences and
in accordance with the National Institutes of Health
Guide for Care and Use of Laboratory Animals. All
efforts were made to minimize the number of animals
used and their suffering.
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Anxiolytic activity was measured using the elevated
plus-maze procedure [11]. The maze consisted of two
opposite open (30 cm×5 cm×0.2 cm) and two opposite
closed (30 cm×5 cm×15 cm) arms, extending from a
central platform (5 cm ×5 cm) and elevated to a height
of 45 cm above the floor. The entire maze was made of
clear Plexiglas. Mice were individually placed on the
center of the maze facing an open arm, and the number
of entries and the time spent in the closed and open
arms were recorded during a 5 min observation period.
Arm entries were defined as the placement of all four
paws into an arm. The percentage of open-arm entries
(open/total entries×100) was calculated for each animal.
The compound Valeriana jatamansi Jones and saline
were administered orally 1 h before testing and the posi-
tive controls were treated with diazepam 30 min before
evaluation in the maze. All tests were carried out on the
tenth or last day of treatment. After each trial, the ap-
paratus was cleaned with 30% alcohol.
Light/dark box
The apparatus (45×21×21cm) consisted of two compart-
ments with one third painted white and two thirdsFigure 1 HPLC profile of Hesperidin(a) and sample solution(b) using a
a Agilent W C18 column, 5 μm, 150 × 4.6mm , 35°Cwith UV detectionpainted black, and these compartments were separated
by a divider with a 3.5×3.5cm opening at floor level
[12,13]. The white compartment was illuminated by
2×60 W lamps. Each mouse was gently placed in the
corner of the white area away from the dark chambers
and monitored over a 5-min observation period. The
number of transfers from one compartment to the other
and the time spent in the illuminated side was measured.
All sessions were recorded by a camera linked to a
monitor in an adjacent room to avoid distractions. After
testing each mouse, the apparatus was thoroughly
cleaned with both wet and dry cloths.
Spontaneous activity
To rule out any unspecific locomotor effects of the com-
pound Valeriana jatamansi Jones on our measures of
anxiolytic effects, the activity of individual mouse was
recorded by a computer-based system (Anilab, Ningbo,
China) for locomotor activity.
Statistical analysis
The data are expressed as the mean ± S.E.M. The statis-
tical analysis was carried out by a one-way analysis of
variance (ANOVA) followed by Student-Newman-Keul’scetonitrile - 0.3% phosphoric acid (20∶80, v/v) at 1.0mL/min on
at 280 nm.
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Significance was accepted at a P <0.05.
Results
HPLC assays
As Valeriana jatamansi Jones was used as monarch
drug, hesperidin content was selected for the quality
control components. The results showed that the
hesperidin in the sample produced a well-resolved peak,
and the resolution with its adjacent chromatographic
peaks was more than 1.5 (Figure 1). For linearity, stock
solutions of 1μL, 2μL, 3μL, 4μL, 5μL, and 8μL were
injected. The calibration curve was prepared with the
absolute amount (μL) as independent variable (X) and
the peak area of Hesperidin as dependent variable (Y).
The corresponding regression equations was computed
and found to be: Y=1625.5X +45.087, R=0.9999. A linear
relationship was obtained in the range of 0.392–
3.136 μg. To test the precision of the assay, reproducibil-
ity was calculated by analyzing 6 samples. The precisionFigure 2 Behavioral outcome of compound Valerianae Jatamansi Jon
time spent in open arms. (b) The percentage of open arms entries. (c) The
**P<0.01 vs. control group. One way ANOVA with Student-Newman-Keul’sresults showed a RSD of 0.44% (n=6). To test the stabil-
ity of the assay, the sample solution was analyzed every
2 h over 10 h (n =6). RSD=0.72% (n=6).
Elevated plus-maze
A one-way ANOVA indicated significant differences
among the groups in the time spent in the open arms of
the elevated plus maze (F4,72=7.45, P<0.01; Figure 2a)
and the percentage of open-arm entries (F4,72=16.70,
P < 0.01; Figure 2b). Compound Valeriana jatamansi
Jones at concentrations of 2.4 and 4.8 g/kg significantly
increased the percentage of time spent in the open arms
and the number of entries into the open arm, compared
to the saline-treated group (P < 0.05). No differences
were observed in the total arm entries among all groups
(F4,72=0.89, P>0.05; Figure 2c). After the mice treated
with compound Valeriana jatamansi Jones were co-
administered flumazenil, there were no differences in
the percentage of time spent in the open arms
(F4,72=0.49, P>0.05; Figure 3a) or the number of entriese during 5 min on the elevated plus-maze. (a) The percentage of
total number of entries. Bars represent mean ± S.E.M. *P<0.05 or
post hoc test.
Figure 3 Behavioral outcome of flumazenil on the anxiolytic-like effect of compound Valerianae Jatamansi Joneduring 5 min on the
elevated plus-maze. (a) The percentage of time spent in open arms. (b) The percentage of open arms entries. Bars represent mean ± S.E.M.
*P<0.05 or **P<0.01 vs. control group. One way ANOVA with Student-Newman-Keul’s post hoc test.
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all groups.Light–dark box test
As shown in Figure 4, one-way ANOVA revealed signifi-
cant differences among the five groups in both the time
spent in the light compartment (F4,69=7.236, P < 0.01)
and the number of transitions between compartments
(F4,69=10.73, P< 0.01). Compared with the saline-treated
mice, treatment with compound Valeriana jatamansi
Jones at doses of 2.4g/kg and 4.8g/kg significantly
increased the time spent in the light compartment and
the number of transitions between compartments (both
P< 0.05). After the mice treated with compound Valeri-
ana jatamansi Jones were co-administered flumazenil
(3mg/kg; i.p.), the time spent in the light compartment
(F4,69=1.805, P>0.05; Figure 5a) and the number oftransitions between compartments (F4,69=1.531, P>0.05;
Figure 5b) was reduced.
Spontaneous activity
A one-way ANOVA indicated significant differences
among the groups in the time spent in the open arms of
the elevated plus maze (F4,72=3.123, P<0.05; Figure 6).
Diazepam significantly reduced spontaneous activity in
animals at 6 mg/kg (P<0.05) compared to the saline
group. However, there were no significant differences
among saline-treated animals and those treated with
compound Valeriana jatamansi Jones at 1.2, 2.4, or 4.8
g/kg (P>0.05).
Discussion
Based on a previous study that showed anxiolytic effects
of compound Valeriana jatamansi Jones in rats [10], we
further tested the anxiolytic effects of this formulation in
Figure 4 Behavioral outcome of compound Valerianae
Jatamansi Jone during 5 min in the light–dark box. (a) The
numbers of transition. (b) Time spent in light compartment. Bars
represents mean ± S.E.M. *P<0.05 or **P<0.01 vs. control group. One
way ANOVA with Student-Newman-Keul’s post hoc test.
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gated the mechanism of action underlying the
anxiolytic-like effect of compound by pre-treating ani-
mals with antagonists of benzodiazepine (flumazenil,
3mg/kg) prior to evaluation using EPM and LDB. We
found that compound Valeriana jatamansi Jones exhib-
ited anxiolytic-like activity, which may be related to the
modulation of GABA(A) receptors. The combination of
our results and those of a previous study strongly sup-
port the idea that compound Valeriana jatamansi Jones
produces anxiolytic effects without inducing sedative
side effects. These findings may support the develop-
ment of potent and selective anxiolytic agents.
The EPM is one of the most popular animal models of
anxiety [14,15]. It has been widely used to screen drug
effects [16-18] because of its use of natural conditions
and stimuli to induce anxiety, such as a fear of a new,
bright, and open space and the fear of balancing on a
relatively narrow raised surface [19]. This study also
used the EPM model to evaluate the anxiolytic effects of
compound Valeriana jatamansi Jones. As expected,compound Valeriana jatamansi Jones (2.4 and 4.8 g/kg)
significantly increased time spent and entries into the
open arms of EPM. Moreover, the anxiolytic effects of
the compound Valeriana jatamansi Jones (4.8 g/kg)
were similar to those of diazepam (2mg/kg). The main
potential confounding factors in this procedure are
changes in basal locomotor activity, which can be in-
ferred from the total number of entries. However, the
compound Valeriana jatamansi Jones did not alter total
arm exploration in the elevated plus maze, suggesting
that this drug induces specific anxiolytic-like effects.
The light/dark box test is another widely used animal
model of anxiety. It is based on the innate aversion of
rodents to bright areas and on the spontaneous explora-
tory behaviors of rodents in response to novel environ-
ments and light [13]. Previous studies reported that
benzodiazepines can increase the transitions between
the two compartments and the time spent in the light
compartment, indicating anxiolytic effects [20,21]. In the
present study, anxiolytic activity of the combined extract
was observed at doses of 2.4 and 4.8g/kg in mice. Both
of these doses significantly increased the number of
transitions between the compartments and the time
spent in the light compartment of LDB.
GABA (A) receptors are the most prevalent inhibitory
neurotransmitter receptors in the brain. Most of them
have separate modulatory sites that are sensitive to ben-
zodiazepines. Benzodiazepines receptor agonists are
commonly prescribed for the treatment of insomnia,
anxiety disorders, and seizures, and these effects can be
blocked by the antagonist flumazenil. In a previous bind-
ing assay [10], the binding of [3H]Ro 15–1788 (flumaze-
nil) to the benzodiazepine binding site in washed crude
synaptosomal membranes from rat cerebral cortex was
affected by compound Valeriana jatamansi Jones. These
data indicate that the anxiolytic-like effects of compound
Valeriana jatamansi Jones may be mediated by benzodi-
azepine binding site modulation at GABA(A) receptors.
However, the EC50 of this formulation is approximately
0.5 mg/mL. As such, it is hard to say whether this is a
sufficient potency to produce in vivo neurochemical and
behavioral actions, as the repeated oral application of
compound by g/kg doses may not result in sufficient
brain concentrations. In this study, we intraperitoneally
administered flumazenil to mice 30 min before testing
[22-24]. We observed that the anxiolytic-like effects of
compound were significantly reduced by pre-treatment
with flumazenil. These results further support the
hypothesis that the anxiolytic effects of compound
Valeriana jatamansi Jones are mainly mediated via
benzodiazepine receptors.
Valerian is the main ingredient of this formulation,
and it is one of the most popular herbal supplements for
the treatment of anxiety and insomnia in Europe [25].
Figure 5 Behavioral outcome of flumazenil on the anxiolytic-like effect of compound Valerianae Jatamansi Jone during 5 min in the
light–dark box. (a) The numbers of transition. (b) Time spent in light compartment. Bars represents mean ± S.E.M. *P < 0.05 vs. control group.
One way ANOVA with Student-Newman-Keul’s post hoc test.
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control were tested in the present study. However, we
found that the dose of 2 mg/kg of diazepam did not pro-
duce sedative effects in our preliminary experiments. To
compare the sedative effects between a positive control
drug and compound Valeriana jatamansi Jones, the
dose of diazepam was increased to 6 mg/kg in the loco-
motor activity test. Although this dose of diazepam sig-
nificantly reduced spontaneous activity counts, none of
the three doses of compound Valeriana jatamansi Jones
affected spontaneous activity in the locomotor test. As
such, we found that compound Valeriana jatamansi
Jones induced anxiolytic effects with an absence ofsedative effects. This may be because the doses tested
were too low to yield sedative effects. In addition,
McKernan et al. showed that the GABA(A) receptor α1
subtype mediates the sedative, but not the anxiolytic
effects of benzodiazepines [26]. According to this find-
ing, compound Valeriana jatamansi Jones may be more
selective than diazepam, and not act through the α1 sub-
type but via other GABAA receptor subtypes.
It should be noted that the three doses tested (1.2, 2.4
and 4.8 g/kg) are related to the original formulation but
not to the extract. In the clinic, the dose of the com-
pound Valeriana jatamansi Jones that is used is 31g per
day. When this human dose is converted into an animal
Figure 6 The counts of compound Valerianae Jatamansi Jone
during 5 min in spontaneous activity. Bars represents mean ± S.E.
M. of activity counts in 5 min *P < 0.05 vs. control group. One way
ANOVA with Student-Newman-Keul’s post hoc test.
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between human and mice), it was equivalent to 4.8 g/kg.
Therefore, 4.8 g/kg was chosen as the highest dose
tested in this study, which is equal to 934 mg/kg extract
of compound Valeriana jatamansi Jones. Unlike the
regular formulation extraction process, Valeriana jata-
mansi Rhizoma et Radix, ziziphi spinosae Semen, Albi-
ziae Cortex, and Junci Medulla were extracted by
different solvents and methods. This was because the
active constituents of these drugs are all sensitive to
water temperature. An orthogonal experimental design
method was performed to optimize the extraction
process of the four herbs as described previously [27].
Briefly, in an L9 (3
4) orthogonal test, the solid–liquid
ratio, ethanol concentration, solvent amount, extraction
times were determined. The extraction process of
Valeriana jatamansi Rhizoma et Radix or Junci Me-
dulla was determined by the content of hesperidin and
the total extract. The optimum extraction condition of
ziziphi spinosae Semen or Albiziae Cortex was deter-
mined by the content of jujuboside A. According to
the original formulation and the herb extracting yield,
the four extracts (Valeriana jatamansi Rhizoma et
Radix, Ziziphi Spinosae Semen, Albiziae Cortex and
Junci Medulla) were then mixed with a ratio of 5:3:5:1
to get the compound Valeriana jatamansi Jones.
As a positive control drug, diazepam exerted anxiolytic
effects after a single dose (2 mg/kg, p.o.). However, in
the present study, the anxiolytic activity was examined
after the mice were given compound Valeriana jata-
mansi Jones for 10 days. Since previous studies have
shown that many drugs elicited anxiolytic effects after
administration for 7 days [28,29], it is possible to test
the anxiolytic activity of the formulation using the EPM
and LDB after administration for less than 10 days. In
addition, previous researchers have indicated thatetiology of anxiety may be related to the levels of
monoamine neurotransmitters and neuroendocrine sys-
tem [30]. Therefore, further studies are needed to iden-
tify these anxiolytic mechanisms.
Conclusions
The present study further supports the hypothesis that
compound Valeriana jatamansi Jones exert anxiolytic
action but no sedative effects in mice and that this effect
might be mediated by benzodiazepine receptors.
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